Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Journal of Hepatology Année : 2022

Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH

Résumé

BACKGROUND & AIMS : The LIVIFY trial investigated the safety, tolerability, and efficacy of vonafexor, a second-generation, non-bile acid farnesoid X receptor agonist in patients with suspected fibrotic non-alcoholic steatohepatitis (NASH). METHODS : This double-blind phase IIa study was conducted in two parts. Patients were randomised (1:1:1:1) to receive placebo, vonafexor 100 mg twice daily (VONA-100BID), vonafexor 200 mg once daily (VONA-200QD), or 400 mg vonafexor QD (VONA-400QD) in Part A (safety run-in, pharmacokinetics/pharmacodynamics) or placebo, vonafexor 100 mg QD (VONA-100QD), or VONA-200QD (1:1:1) in Part B. The primary efficacy endpoint was a reduction in liver fat content (LFC) by MRI-proton density fat fraction, while secondary endpoints included reduced corrected T1 values and liver enzymes, from baseline to Week 12. RESULTS : One hundred and twenty patients were randomised (Part A, n = 24; Part B, n = 96). In Part B, there was a significant reduction in least-square mean (SE) absolute change in LFC from baseline to Week 12 for VONA-100QD (-6.3% [0.9]) and VONA-200QD (-5.4% [0.9]), vs. placebo (-2.3% [0.9], p = 0.002 and 0.012, respectively). A >30% relative LFC reduction was achieved by 50.0% and 39.3% of patients in the VONA-100QD and VONA-200QD arms, respectively, but only in 12.5% in the placebo arm. Reductions in body weight, liver enzymes, and corrected T1 were also observed with vonafexor. Creatinine-based glomerular filtration rate improved in the active arms but not the placebo arm. Mild to moderate generalised pruritus was reported in 6.3%, 9.7%, and 18.2% of participants in the placebo, VONA-100QD, and VONA-200QD arms, respectively. CONCLUSIONS : In patients with suspected fibrotic NASH, vonafexor was safe and induced potent liver fat reduction, improvement in liver enzymes, weight loss, and a possible renal benefit.
Fichier principal
Vignette du fichier
PIIS0168827822031609.pdf (977.82 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification

Dates et versions

hal-04093669 , version 1 (10-05-2023)

Identifiants

Citer

Vlad Ratziu, Stephen A Harrison, Véronique Loustaud-Ratti, Christophe Bureau, Eric Lawitz, et al.. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. Journal of Hepatology, 2022, 78 (3), pp.479 - 492. ⟨10.1016/j.jhep.2022.10.023⟩. ⟨hal-04093669⟩
40 Consultations
246 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More